Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.62 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031149 | 0.85 | CHRNA7 (0.54) | CHRNA7L3MBTL1HSD11B1HTR3ACHRNA3 | |
| SCHEMBL4028418 | 0.84 | CHRNA7 (0.52) | CHRNA7HPGDHSD11B1HTR3ACHRNA3 | |
| SCHEMBL4031884 | 0.84 | CHRNA7 (0.52) | CHRNA7HTR3ACHRNA3MGLL | |
| SCHEMBL4030570 | 0.83 | CHRNA7 (0.60) | CHRNA7L3MBTL3L3MBTL1HTR3ACHRNA3 | |
| SCHEMBL4032087 | 0.82 | L3MBTL3 (0.58) | CHRNA7L3MBTL3L3MBTL1HPGDHSD11B1 | |
| SCHEMBL4700437 | 0.81 | CHRNA7 (0.55) | CHRNA7HPGDHSD11B1HTR3A | |
| SCHEMBL373468 | 0.80 | CHRNA7 (0.55) | CHRNA7HPGDHSD11B1HTR3A | |
| SCHEMBL4035487 | 0.80 | MEN1 (0.51) | CHRNA7HPGDHSD11B1HTR3AMGLL | |
| SCHEMBL4705060 | 0.79 | CHRNA7 (0.48) | CHRNA7HTR3A | |
| SCHEMBL373302 | 0.78 | CHRNA7 (0.62) | CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539764-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016616-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1539764-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539765-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016617-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016616-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | CHRNA7 6/4885L3MBTL3 4614/4885L3MBTL1 3945/4885 |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | CHRNA7 1/4885L3MBTL3 4464/4885L3MBTL1 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.